Tafasitamab with lenalidomide as add-on therapy for previously treated follicular lymphoma or marginal zone lymphoma

Tafasitamab with lenalidomide (as an add-on to rituximab) is in clinical development for treating relapsed or refractory follicular lymphoma (FL) of any grade except 3B, or marginal zone lymphoma (MZL). These are slow-growing types of cancer that develop when white blood cells, called B lymphocytes, grow out of control. Common symptoms include painless swellings in the neck, armpit or groin, night sweats, weight loss or high temperatures. MZL may cause these or additional symptoms. These lymphomas often respond well to initial treatment but later return (relapsed cancer). Cancer that does not respond to treatment is called refractory. Most people with FL or MZL live for many years but may have multiple relapses requiring treatment. Relapsed disease often responds less well to treatment so there is a need for additional therapy options.